Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

Published:2015-07 Issue:1 Volume:68 Page:154-160
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Iacovelli Roberto,Massari Francesco,Albiges Laurence,Loriot Yohann,Massard Christophe,Fizazi Karim,Escudier Bernard

Publisher

Elsevier BV

Subject

Urology

Reference35 articles.

1. Cancer facts and figures 2013,2013

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

3. Estimates of global cancer prevalence for 27 sites in the adult population in 2008;Bray;Int J Cancer,2013

4. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia;Gunningham;Cancer Res,2001

5. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions—International Pediatric Low-Grade Glioma Coalition;Neuro-Oncology;2024-05-14

2. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma;Expert Review of Precision Medicine and Drug Development;2024-03-18

3. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study;European Urology;2024-03

4. Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study;Pharmaceuticals;2024-01-17

5. The role of belzutifan, an inhibitor of hypoxia-inducible factor, for renal cell carcinoma in adults with Von Hippel–Lindau disease: a review;Drugs & Therapy Perspectives;2023-11